Sanofi

Template:Short description Template:Use dmy dates {{#invoke:Infobox|infobox}}Template:Template other Template:Main other{{#invoke:Check for clobbered parameters|check|nested=1|template=Infobox company|cat=Template:Main other|name; company_name|logo; company_logo|logo_alt; alt|trade_name; trading_name|former_names; former_name|type; company_type|predecessors; predecessor|successors; successor|foundation; founded|founders; founder|defunct; dissolved|hq_location; location|hq_location_city; location_city|hq_location_country; location_country|num_locations; locations|areas_served; area_served|net_income; profit|net_income_year; profit_year|owners; owner |homepage; website }}{{#invoke:Check for unknown parameters|check|unknown=Template:Main other|preview=Page using Template:Infobox company with unknown parameter "_VALUE_" | ignoreblank=y | alt | area_served | areas_served | assets | assets_year | aum | brands | company_logo | company_name | company_type | defunct | dissolved | divisions | embed | equity | equity_year | fate | footnotes | former_name | former_names | foundation | founded | founder | founders | genre | homepage | hq_location | hq_location_city | hq_location_country | incorporated | image | image_alt | image_caption | image_size | image_upright | income_year | industry | ISIN | key_people | location | location_city | location_country | locations | logo | logo_alt | logo_caption | logo_class | logo_size | logo_upright | members | members_year | module | name | native_name | native_name_lang | net_income | net_income_year | num_employees | num_employees_year | num_locations | num_locations_year | operating_income | owner | owners | parent | predecessor | predecessors | production | production_year | products | profit | profit_year | rating | ratio | revenue | revenue_year | romanized_name | services | subsid | successor | successors | traded_as | trade_name | trading_name | type | website| qid | fetchwikidata | suppressfields | noicon | nocat | demo | categories }}

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 2023, the company’s seat in Forbes Global 2000 was 89.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is the world's largest producer of vaccines through its subsidiary Sanofi Pasteur.<ref>Template:Cite news Template:Dead link Template:Cbignore</ref>

HistoryEdit

Sanofi-SynthélaboEdit

Sanofi was founded in 15 February 1973<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly;<ref>Template:Cite book</ref> Labaz developed benziodarone in 1957.<ref>Template:Cite book</ref>Template:Rp In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company whose 1992, sales totaled about US$104 million.<ref name="PL1993">Staff, The Pharma Letter. Sept 20, 1993 Sanofi Extends Holding in Chinoin</ref><ref>Chinoin listing in at securities.com Page accessed 5 February 2016</ref> In the same year, Sanofi made its first significant venture into the US, and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994.<ref name=PL1993/><ref name="SterlingHist">Template:Cite journal</ref> Sanofi was incorporated under the laws of France in 1994, as a société anonyme, a form of limited liability company.<ref name="20F-2002">Sanofi-Synthélabo Form 20F for the Fiscal Year ended 31 December 2002</ref>Template:Rp

Synthélabo was founded in 1970, through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834)б and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L'Oréal acquired the majority of its share capital.<ref name=20F-2002/>Template:Rp In 1991, Synthelabo acquired Laboratories Delalande<ref>Denis Cosnard for Les Echos. 11 December 1991. Synthélabo s'offre Delalande</ref> and Laboratoires Delagrange, and through this deal picked up the product metoclopramide.<ref>Denis Conard for Les Echos. 17 October 1991 Synthélabo rachète les laboratoires Delagrange</ref><ref>Bibliothèque nationale de France Laboratoires Delagrange Page accessed 24 August 2016</ref>

File:Sanofi Synthelabo Logo.svg

Logo for Sanofi-Synthélabo (1999—2004)

Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo; at the time of the merger, Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France.<ref name=20F-2002/>Template:Rp<ref>Tom Meek for PMLiVE 24 May 2013 A look back at Sanofi's merger with Synthélabo</ref>

The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.<ref name=20F-2002/>Template:Rp

AventisEdit

Aventis was formed in 1999, when the French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Cassella, Roussel Uclaf, and Marion Merrell Dow. Hoechst AG, the majority partner at the time in Hoechst Marion Roussel, was itself a merger of two of the three forcibly separated subsidiaries of IG Farben, exploiter of Auschwitz slave labor and supplier of Zyklon B during The Holocaust.<ref>Joseph Borkin: The Crime and Punishment of I.G. Farben (New York: The Free Press, 1990), p. 163.</ref> The merged company was based in Schiltigheim, near Strasbourg, France.<ref name="Aventis-Form20F2002">Aventis Form 20-F for the fiscal year ended 31 December 2002</ref>Template:Rp<ref name="Bris">Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis, Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007</ref>Template:Rp<ref name="Burns">Lawton Robert Burns The Business of Healthcare Innovation Cambridge University Press, 26 July 2012</ref>Template:Rp

At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc Agro, Rhône-Poulenc Animal Nutrition, and Merial, and a 67 percent share in Rhodia, a speciality chemicals company.<ref name=Bris/>Template:Rp Hoechst, one of the companies that resulted from the post-WWII split of IG Farben, had seven primary businesses: Hoechst Marion Roussel (pharmaceuticals), AgrEvo (a joint venture with Schering in crop protection agents and pest control products), HR Vet (veterinary products), Dade Behring (diagnostics), Centeon, Celanese (chemicals), and Messer (chemicals).<ref name=Bris/>Template:Rp Merieux has been in the business of selling blood products, and in the 1980s, during the AIDS epidemic, Merieux and other companies were involved in scandals related to HIV-contaminated haemophilia blood products that were sold to developing nations.<ref name="NYTimes1996">Template:Cite news</ref>

In 2000, Aventis and Millennium Pharmaceuticals, a US biotechnology company formed to discover new drugs based on the then-new science of genomics, announced that Aventis would make a $250M investment in Millennium and would pay $200M to Millennium in research fees over five years, one of the largest such deals between a big pharmaceutical company and a biotech company at the time.<ref>Template:Cite news</ref>

In late 2000, in the midst of the recall of Starlink, its genetically modified maize product, Aventis announced that it had determined to sell off Aventis Cropscience, the seed and pesticide business unit it had created from the agriculture businesses of its predecessors.<ref>Template:Cite news</ref> In October 2001, Bayer and Aventis announced that Bayer would acquire the unit for about $6.6 billion; the unit became Bayer CropScience, making Bayer the world's second-largest agrochemical company behind Syngenta.<ref>CNN Money. 2 October 2001 Bayer buys CropScience</ref>

In 2003, Aventis entered into a collaboration with Regeneron Pharmaceuticals, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, which was then in Phase I clinical trials. Aventis invested $45 million in Regeneron and made an upfront payment of $80 million in cash.<ref>Candace Hoffmann for First Word Pharma. 8 September 2003 Aventis inks deal with Regeneron for collaboration on cancer therapy</ref> Regeneron partnered the use of the drug with Bayer Healthcare in the field of proliferative eye diseases, and under the name Eylea it was approved by the US Food and Drug Administration (FDA) in 2011;<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> after several setbacks in clinical trials,<ref>Template:Cite journal</ref> Regeneron and Sanofi got the drug approved for metastatic colorectal cancer in combination with other agents, under the brand name Zaltrap in 2012.<ref name="ZaltrapFDA">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Sanofi-Aventis mergerEdit

Sanofi-Aventis was formed in 2004, when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid for Aventis worth €47.8 billion. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis went so far as to enact poison pill provisions and to invite Novartis to enter merger negotiations.<ref>Template:Cite news</ref> The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The French government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis and for Aventis to accept the offer<ref>Template:Cite news</ref> and by rejecting Aventis's poison pill proposal.<ref>Template:Cite news</ref> One of the largest risks in the deal for both sides was the fate of the patents protecting Clopidogrel (Plavix), which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue.<ref>Kimberly S Cleaves and Ann M Thayer Warning, merge with care: Sanofi-Aventis Modern Drug Discovery, August 2004:21-26</ref>

Post-merger activitiesEdit

In 2006, Iraqis infected with HIV sued Sanofi and Baxter over HIV-contaminated haemophilia blood products sold by Merieux in the 1980s.<ref>Template:Cite news</ref> In 2006, the US patents on clopidogrel (Plavix) were challenged when a Canadian generics company, Apotex, filed an Abbreviated New Drug Application under the Hatch-Waxman Act, received FDA approval, and started marketing a generic formulation of clopidogrel. While Sanofi-Aventis and its partner in the drug, Bristol Myers Squibb (BMS), were able to get an injunction to stop Apotex from selling it,<ref>BMS Press Release. 8 December 2006 Preliminary Injunction Against Apotex Upheld on Appeal</ref> the case became complicated when settlement negotiations fell apart twice – the second time because of an oral agreement made by BMS CEO Peter Dolan that BMS failed to disclose to the Federal Trade Commission during the review of the settlement agreement to ensure that it did not violate antitrust law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan's dismissal by BMS.<ref>Aaron Smith for CNNMoney.com 26 October 2006 Bristol CEO Dolan gets fired: Company says it heeded request of a federal monitor</ref> Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent,<ref>Donald Zuhn for Patent Docs. 9 November 2011 Sanofi-Aventis v. Apotex Inc. (Fed. Cir. 2011)</ref> which it paid in full by February 2012.<ref>Linda a. Johnson for Associated Press 8 February 2012 Apotex pays Bristol, Sanofi damages over Plavix Template:Webarchive</ref> Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement; Apotex lost a jury trial in March 2013.<ref>Carolina Bolado for Law360 14 March 2013. Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal</ref>

In 2007, Sanofi-Aventis expanded on Aventis's prior relationship with Regeneron Pharmaceuticals; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million per year for five years, under which Regeneron would use its monoclonal antibody discovery platform to create new biopharmaceuticals, to which Sanofi-Aventis gained the exclusive right to co-develop.<ref name="RegenExpand">Template:Cite news</ref> In 2009, the companies expanded the deal to $160 million per year and extended it to 2017.<ref name=RegenExpand/><ref name="GEN2009">Genetic Engineering and Biotechnology News. 11 November 2009 Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance</ref> Template:As of, the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6 receptor as a treatment for rheumatoid arthritis, another targeted nerve growth factor for the treatment of pain, and another targeted delta-like ligand 4 as a cancer treatment.<ref name=GEN2009/>

Between 2008, when Chris Viehbacher was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming patent cliffs and the growth of the consumer healthcare segment.<ref>FierceBiotech. Sanofi-Aventis: A timeline of biopharma deals</ref><ref>Andy Tisman for IMS Health 2010 The Rising Tide of OTC in Europe</ref><ref name=Chattem/> In September, Zentiva was acquired for €1.8 billion, expanding the group's presence in eastern European markets.<ref>Template:Cite news</ref>

In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company there, was acquired for about $635 million.<ref name="Law360Medley">Leigh Kamping-Carder for Law360. 20 May 2010 Brazil Clears Sanofi's $635M Medley Pharma Buy</ref> Sanofi outbid Teva Pharmaceuticals.<ref>Gareth Macdonald for PharmaTechnologist, 15 April 2009 Sanofi beats Teva in Medley melee</ref> The deal was approved by Brazil's antitrust authorities in May 2010.<ref name=Law360Medley/> Later that year, Indian vaccine manufacturer Shantha Biotechnics was acquired for $784 million.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In October Sanofi-Aventis announced that it would lay off about 1700 US employees (about 25% of its US workforce) because of restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation, and oncology.<ref>Template:Cite news</ref>

In 2010, US consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion.<ref name="Chattem">Template:Cite news</ref> In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.<ref>Phil Serafino for Bloomberg News. 28 October 2010 Sanofi-Aventis to Buy BMP Sunstone to Expand in China</ref>

Name change, acquisitions and investmentsEdit

The company dropped the -Aventis suffix of its name on May 6, 2011, after receiving approval at its annual general meeting. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.<ref>Template:Cite news</ref>

In 2011, Genzyme Corporation was acquired for around $20.1 billion. This biotechnology company, headquartered in Cambridge, Massachusetts, specializes in the treatment of orphan diseases, renal diseases, endocrinology, oncology, and biosurgery.<ref>Template:Cite news</ref>

In January 2012, Sanofi co-invested in the $125 million Series A financing of Warp Drive Bio. Sanofi sought support for its internal cancer research program and also took on an obligation to acquire Warp Drive if certain milestones were met.<ref>Template:Cite news</ref>

In January 2014, Genzyme and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under the deal, Genzyme obtained further rights to patisiran, an RNAi treatment for transthyretin-mediated amyloidosis – a condition that can result in familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and obtained rights to other compounds in Alnylam's pipeline.<ref>Template:Cite news</ref>

In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of Coppertone sunblock and the antihistamine Claritin; bids were expected to range between $10 billion and $12 billion.<ref>Template:Cite news</ref>

In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy.<ref>Template:Cite news</ref> Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when Bayer Healthcare board chairman Olivier Brandicourt (appointed by Sanofi on 19 February 2015<ref>Template:Cite press release</ref>) took over. Before Brandicourt even started his new job, French government ministers Stéphane Le Foll and Ségolène Royal attacked the $4.5 million golden handshake he was getting from Sanofi – and his pay of about $4.7 million a year.<ref>Template:Cite news</ref> Furthermore, in 2014, the business took a 66% stake in Globalpharma, a Dubai-based generics manufacturer.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In July 2015, Genzyme announced that it would acquire the cancer drug Caprelsa (vandetanib) from AstraZeneca for up to $300 million.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In the same month, the company announced a new global collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> with $640 million upfront, $750 million for proof of concept data, and $650 million from the development of REGN2810.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In June 2016, the company announced that it had struck an asset-swap deal with Boehringer Ingelheim. Sanofi would sell its Merial animal health division (valuing it at €11.4 billion), while acquiring Boehringer's consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal meant that Sanofi was now one of the global consumer healthcare leaders by market share.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In July 2017, the company announced its intention to acquire Protein Sciences, a privately held Connecticut-based vaccines biotechnology company, for $650 million and with up to $100 million in milestone achievements.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In January 2018, Sanofi announced that it would acquire Bioverativ for $11.6 billion<ref>Template:Cite news</ref> and days later announced that it would acquire Ablynx for €3.9 billion ($4.8 billion).<ref>Template:Cite news</ref>

In December 2019, the company announced that it would acquire Synthorx for $2.5 billion ($68 per share), adding the lead product candidate THOR-707 (SAR444245), a form of interleukin-2 (IL-2) being developed for use against multiple solid tumors.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In October 2022, Sanofi announced that it had stopped Phase 2 studies of THOR-707 (SAR444245) because the drug's efficacy “was lower than projected”.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Sanofi would take a roughly $1.6 billion impairment charge because of delays to the program.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In May 2020, Regeneron announced that it would repurchase around $5 billion of its shares held directly by Sanofi. Before the transaction, Sanofi had held 23.2 million Regeneron shares.<ref>Template:Cite news</ref> In June, the company announced that it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments.<ref>Template:Cite news</ref> The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It used recombinant protein-based technology for Sanofi's flu vaccine along with GSK's pandemic technology and was seeking regulatory approval by the first half of 2021.<ref>Template:Cite news</ref> Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In August, Sanofi announced that it would acquire Principia Biopharma for $3.7 billion, acquiring its BTK inhibitor program.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite news</ref> The acquisition was completed in September 2020.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In November, Sanofi announced that it would acquire Kiadis Pharma for €308 million (around $359 million, or €5.45 per share), expanding its immuno-oncology pipeline with the acquisition of Kiadis's three clinical compounds: K-NK002 in Phase II trials for hematopoietic stem cell transplants in blood cancer, K-NK003 for relapsed or refractory acute myeloid leukemia, and K-NK-ID101 for COVID-19.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In January 2021, Sanofi announced that it would buy the British biotech Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion.<ref>Template:Cite news</ref><ref>Template:Cite press release</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In April, the business announced that it would acquire Tidal Therapeutics for up to $470m.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> in August the company announced that it would acquire Translate Bio and its mRNA vaccine technology for $3.2 billion.<ref>Template:Cite news</ref> On 8 September 2021, Sanofi announced that it would acquire US biotech company Kadmon Corporation for $1.9 billion<ref>Template:Cite news</ref> On 18 November 2021, it was reported that Sanofi would be investing $180 million in French startup Owkin, whose predictive algorithms aim to improve the research and development of new cures against cancer.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In December, the company announced that it would acquire Origimm Biotechnology GmbH and its acne vaccine candidate (ORI-001),<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite news</ref> as well as Amunix Pharmaceuticals, for an initial $1 billion plus potentially $200 million in additional milestones.<ref>Template:Cite news</ref>

In April 2022, Sanofi broke ground on its biggest industrial investment, a $638m vaccine and enzymes production facility in Tuas, Singapore, targeted for completion in 2025.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In March 2023, the company announced it would acquire Provention Bio and its type 1 diabetes therapy pipeline.<ref>Template:Cite news</ref>

In the fall of 2023, Sanofi announced plans to separate the OTC and focus on its key prescription production, increasing investment and reducing costs. The most likely way to separate a non-prescription division (about 11,000 employees, 2023 revenue — over $4 billion) is to create a public company headquartered in France. The division is planned for the fourth quarter of 2024.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In December 2023, the company has signed a 140 million dollars partnership with Aqemia, a company that solves a mathematical equation that eliminates the need for heavy computing facilities with large computing power.<ref>Template:Cite news</ref>

In January 2024, Sanofi announced that it had agreed to buy a U.S. biotech firm Inhibrx for up to $2.2 billion, with a focus on obtaining Inhibrx's INBRX-101, an experimental treatment for Alpha-1 Antitrypsin Deficiency (AATD), an inherited rare disease that causes progressive deterioration of the lung tissue.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The post-acquisition company now employs more than 90,000 employees in 90 countries.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In October 2024, Sanofi and CD&R entered exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In May 2025, Sanofi announced the buyout of Vigil Neuroscience for $470 million.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Company financialsEdit

Historical financial data (in billions of euro)<ref>{{#invoke:citation/CS1|citation
CitationClass=web }}</ref><ref>{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref><ref name="Form 20-F 2018">{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1\|citation	CitationClass=web }}</ref>	Year	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2023
Revenue	6.069	7.448	8.048	14.87	27.31	28.37	28.05	27.57	29.31	30.38	33.39	34.95	30.97	31.69	34.54	33.82	35.07	34.46	36.13	43.07
Net Income	1.098	1.640	1.865	-3.665	2.202	4.006	5.263	3.851	5.265	5.467	5.646	4.888	3.716	4.390	4.287	4.800	8.42	4.31	2.81	5.43
Assets	18.23	17.36	17.42	82.85	86.24	77.76	71.91	71.99	80.25	85.26	100.7	100.4	96.06	97.39	102.3	104.7	99.81	111.41	112.74	126.4
Equity	12.75	12.60	12.74	41.63	46.40	45.60	44.54	44.87	48.32	53.10	56.19	57.35	56.9	56.12	58.05	57.72	58.07	58.88	58.93	74.35

Note. In 2001–2004: Sanofi-Synthélabo; in 2004–2011: Sanofi-Aventis.

Acquisition historyEdit

Template:Hidden begin Template:Tree list

Sanofi
- Sanofi–Aventis
  - Aventis (Merged 2004)
    - Rhône-Poulenc (Merged 1999)
      - A. Nattermann (Acq 1986)
      - William H. Rorer, Inc. (Merged 1990)
      - Centeon
      - Pasteur Merieux
      - Rhône-Poulenc Agro
      - Rhône-Poulenc Animal Nutrition
      - Merial (Sold to Boehringer Ingelheim 2016)
      - Rhodia
    - Hoechst Marion Roussel (Merged 1999)
      - AgrEvo
      - HR Vet
      - Dade Behring
      - Centeon
      - Celanese
      - Messer
      - Roussel Uclaf (Acq 1997)
  - Sanofi-Synthélabo (Merged 2004)
    - Sanofi (Est 1973 as subsidiary of Elf Aquitaine)
      - Midy
      - Sterling Winthrop (Acq 1994)
    - Synthélabo
      - Laboratoires Dausse (Founded 1834, merged 1970)
      - Robert & Carrière (Founded 1899, merged 1970)
  - Zentiva (Acq 2008)
    - Leciva Slovakofarma (Acq 2003)
    - Sicomed SA Bucharest (Acq 2005)
  - Medley Farma (Acq 2009)
  - Shantha Biotechnics (Acq 2009)
  - Chattem (Acq 2010)
  - Nepentes Pharma (Acq 2010)
  - BMP Sunstone Corporation (Acq 2010)
- Genzyme Corporation (Acq 2011)
  - Whatman Biochemicals Ltd (Acq 1981)
  - Koch-Light Laboratories (Acq 1982)
  - Integrated Genetics (Acq 1989, spun off 1991)
  - Genecore International (Diagnostic enzyme div, acq 1991)
  - Medix Biotech, Inc. (Acq 1992)
  - Enzymatix Ltd (Acq 1992)
  - Vivigen (Acq 1992)
  - Virotech (Acq 1993)
  - Omni Res srl (Acq 1993)
  - Sygena Ltd (Acq 1994)
  - BioSurface Technology Inc. (Acq 1994)
  - TSI Inc. (Acq 1994)
  - PharmaGenics, Inc. (Acq 1997)
  - Biomatrix (Acq 2000)
  - SangStat Medical Corp. (Acq 2003)
  - Ilex Oncology Inc. (Acq 2004)
  - Bone Care International Inc. (Acq 2005)
  - AnorMED Inc. (Acq 2006)
  - Bioenvision (Acq 2007)
- Protein Sciences (Acq 2017)
- Bioverativ (Acq 2018)
  - True North Therapeutics (Acq 2017)
- Ablynx (Acq 2018)
- Synthorx (Acq 2019)
- Principia Biopharma (Acq 2020)
- Kiadis Pharma (Acq 2020)
- Kymab Ltd (Acq 2021)
- Tidal Therapeutics (Acq 2021)
- Translate Bio (Acq 2021)
- Kadmon Corporation (Acq 2021)
- Origimm Biotechnology GmbH (Acq 2021)
- Amunix Pharmaceuticals (Acq 2021)
- Provention Bio (Acq 2023)
- Inhibrx (Acq 2024)<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

- Vigil Neuroscience (Acq 2025)<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref> Template:Tree list/end Template:Hidden end

ProductsEdit

The following products are listed on the Sanofi Genzyme website. Generic drug names are given in parentheses following the brand name.

– Autoimmune Template:Colbegin

Aubagio (Teriflunomide), small molecule for multiple sclerosis. Approved by the FDA in September 2012.<ref>Template:Cite press release</ref>
Auvi-Q (Epinephrine autoinjector), licensed from Intelliject<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref> and approved by the FDA in 2012, for emergency treatment of life-threatening allergic reactions.<ref>Template:Cite news</ref> Template:Colend Product recall and effects: The epinephrine (adrenaline) auto-injection devices made by Sanofi SA currently on the market in the US and Canada were voluntarily recalled on 28 October 2015.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The reason given by Sanofi was that the products had been found to potentially have inaccurate dosage delivery systems, which might include failure to deliver the drugs.<ref name="auvi-q.com">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="fda.gov">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Sanofi US also added the following warning: If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death, because anaphylaxis is a potentially life‑threatening condition.<ref name="auvi-q.com" />

In its news release on 28 October 2015, Sanofi Canada stated that it was "actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible. Canadian customers were asked to immediately return the Allerject product to their local pharmacy to obtain an alternate epinephrine auto-injector."<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The US Food and Drug Administration (FDA) also filed a news release,<ref name="fda.gov" /> confirming that the recall involved all Auvi-Q currently on the market in the United States. The FDA release went on to provide information for consumers re: exchanging the device for another brand of product, also provided on the Auvi-Q web site. Sanofi US would provide reimbursement for out of pocket costs incurred for the purchase of new, alternate epinephrine auto-injectors with proof of purchase.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The alternate products expected to most commonly replace the recalled Sanofi devices were the EpiPens made by Mylan in the US and by Pfizer—under license from Mylan—in Canada.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Mylan already had an 85% market share of the auto-injectors in the USA<ref>Template:Cite news</ref> in the first half of 2015. Maylan was expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of 2 November 2015. As Bernstein analyst Ronny Gal wrote in a note to clients,"....it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall."<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Gal also believed that the company would eventually have 95% of the epinephrine auto-injector market, according to another Fierce Pharma report on 3 November 2015.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

– Cardiovascular Template:Colbegin

Adenoscan (Adenosine), for arrhythmias, marketed by Astellas.
Altace (Ramipril), for hypertension, marketed by Pfizer.
Arixtra (Fondaparinux), for thrombosis, marketed by GlaxoSmithKline and now owned by Mylan.
Avalide (Irbesartan), for hypertension, marketed by Bristol-Myers Squibb.
Avapro (Irbesartan), for hypertension, marketed by Bristol-Myers Squibb.
Cardizem (Diltiazem), for hypertension, Now owned by Bausch Health.
Cholestagel (Colesevelam), for low-calorie diet and exercise.
Cordarone (Amiodarone), for heart rhythm problems.
Iprivask (Desirudin), for atherothrombosis, Now owned by Bausch Health.
Kynamro (Mipomersen), an antisense drug invented by Isis Pharmaceuticals and acquired by Genzyme in 2008, (pre-Sanofi)<ref>Lisa M. Jarvis for Chemical and Engineering News. 14 January 2008 Isis, Genzyme In Heart Drug Deal</ref> and approved by the FDA in 2013, for the orphan disease homozygous familial hypercholesterolemia.<ref>Template:Cite news</ref>
Lasix (Furosemide), for edema.
Lovenox (Enoxaparin), for thrombosis, (its biggest seller in 2008).<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

Multaq (Dronedarone), for cardiac arrhythmias.
Nitrolingual (Nitroglycerin), for chest pain and angina, marketed by G. Pohl-Boskamp GmbH & Co.
Plavix (Clopidogrel), for atherothrombosis, marketed by Bristol-Myers Squibb.
Praluent (Alirocumab), for heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease, marketed by Regeneron.
Ranexa (Ranolazine), for stable angina, marketed by Gilead Sciences.

Sanofi

HistoryEdit

Sanofi-SynthélaboEdit

AventisEdit

Sanofi-Aventis mergerEdit

Post-merger activitiesEdit

Name change, acquisitions and investmentsEdit

Company financialsEdit

Acquisition historyEdit

ProductsEdit

PipelineEdit

ManagementEdit

StockholdersEdit

Head officeEdit

Collaborative researchEdit

Sanofi PasteurEdit

BCG supply shortage 2012–2014Edit

COVID-19 vaccineEdit

OpellaEdit

AssociationsEdit

Aventis FoundationEdit

See alsoEdit

NotesEdit

ReferencesEdit

External linksEdit